References
- LucchiniEPilottoSSpadaEMelisiDBriaETortoraGTargeting the epidermal growth factor receptor in solid tumors: focus on safetyExpert Opin Drug Saf201413553554924684184
- GutzmerRWollenbergAUgurelSHomeyBGanserAKappACutaneous side effects of new antitumor drugs: clinical features and managementDtsch Arztebl Int2012109813314022419954
- LacoutureMEAnadkatMJBensadounRJClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupport Care Cancer20111981079109521630130
- RobertCSoriaJCSpatzACutaneous side-effects of kinase inhibitors and blocking antibodiesLancet Oncol20056749150015992698
- BorkarDSLacoutureMEBastiSSpectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year reviewSupport Care Cancer20132141167117423151647
- SmithJErlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancerClin Ther200527101513153416330289
- HeidaryNNaikHBurginSChemotherapeutic agents and the skin: An updateJ Am Acad Dermatol200858454557018342708
- RosmanISAnadkatMJTufted hair folliculitis in a woman treated with trastuzumabTarg Oncol201054295296
- KeefeDMBatemanEHTumor control versus adverse events with targeted anticancer therapiesNat Rev Clin Oncol2012929810922182972
- LacoutureMELaiSEThe PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndromeBr J Dermatol2006155485285416965448
- LiuHBWuYLvTFSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisPLoS One201381e5512823383079
- FaehlingMEckertRKuomSKampTStoiberKMSchumannCBenefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment lineOncology2010783–424925820523085
- Perez-SolerRCan rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?Oncology (Williston Park)20031711 Suppl 12232814682120
- CarserJESummersYJTrichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancerJ Thorac Oncol2006191040104117409992
- BrandiGVenturiMDikaEMaibachHPatriziABiascoGCutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacyCutan Ocul Toxicol201332433633823534992
- ChanprapaphKVachiramonVRattanakaemakornPEpidermal growth factor receptor inhibitors: a review of cutaneous adverse events and managementDermatol Res Pract2014201473424924723942
- RudinCMLiuWDesaiAPharmacogenomic and pharmacokinetic determinants of erlotinib toxicityJ Clin Oncol20082671119112718309947
- BentzenSMTrottiAEvaluation of early and late toxicities in chemoradiation trialsJ Clin Oncol200725264096410317827459